Norroy receives China’s clearance for Phase III study of 177Lu-NYM032

Phase 3177Lu-NYM032Positive

AI Analysis

Summary

Norroy Bioscience received NMPA approval to initiate a Phase III clinical trial in China for 177Lu-NYM032, a PSMA-targeted small-molecule radioligand therapy.

Clinical Trial Data

Phase

Phase III

Outcome Details

Approval from NMPA to initiate Phase III clinical trial in China

Importance:6/10

Sentiment:

0.70

regulatory approvalChinaNMPAphase IIIPSMA-targetedradioligand therapy

Related Companies

$BHIC $CHHE $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on September 3, 2026 8:44 AM

Read Original